Squamous cell carcinomas (SCCs) of the head and neck are characterized by high tendency to invade locally and metastasize to lymph nodes. SCC cells express several matrix metalloproteinases (MMPs) and they often harbor mutations in p53 tumor suppressor gene. Collagenase-3 (MMP-13) is speci®cally expressed by tumor cells of SCCs and it apparently plays an important role in their invasion and metastasis. We used adenoviral gene delivery to examine the eect of wild-type p53 on MMP-13 expression in four head and neck SCC cell lines with mutated p53. Adenoviral delivery of p53 resulted in potent inhibition in production of proMMP-13 (by 71 to 92%) and collagenase-1 (MMP-1) (by 27 to 93%) by all cell lines in 24 h, whereas production of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) was not altered. Adenoviral expression of p53 also suppressed invasion of SCC cells through Matrigel by 35%. Expression of cyclin-dependent kinase inhibitor p21 Waf1/Cip1 was induced 24 h after p53 gene delivery in all SCC cell lines, except one, which lacked detectable p21
Introduction
Tumor invasion and metastasis involves detachment of cancer cells from primary tumor, controlled degradation of structural barriers, such as basement membrane and collagenous extracellular matrix (ECM), and migration of cells through degraded matrix. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all ECM components and they obviously play an important role in tumor invasion and tumor-induced angiogenesis (Westermarck and KaÈ haÈ ri, 1999) . At present, 21 human members of the MMP gene family are known and they are divided into subgroups of collagenases, gelatinases, stromelysins, membrane-type MMPs, and other MMPs according to their structure and substrate speci®city (Johansson et al., 2000a) .
Fibrillar collagens are the most abundant structural components of the human connective tissues and it is conceivable, that the ability to degrade them is crucial for invasion and metastasis of neoplastic cells. Members of the collagenase subgroup, i.e. collagenase-1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13) are the only neutral proteinases capable of cleaving native ®brillar collagens of type I, II, III, and V (KaÈ haÈ ri and Saarialho-Kere, 1999). MMP-13 also degrades several other ECM components: type IV, X, and XIV collagens, large tenascin C, ®bronectin, aggrecan, versican and ®brillin-1 (Ashworth et al., 1999; Fosang et al., 1996; KnaÈ uper et al., 1996 KnaÈ uper et al., , 1997 . The wide proteolytic capacity of MMP-13 suggests a role for it as a powerful invasion tool for malignant cells, and in fact, expression of MMP-13 has been detected in various invasive neoplastic tumors, i.e. breast carcinomas (Freije et al., 1994; Heppner et al., 1996) , squamous cell carcinomas (SCCs) of the head and neck (Airola et al., 1997; Cazorla et al., 1998; Johansson et al., 1997a) , vulva (Johansson et al., 1999) , and esophagus (Etoh et al., 2000) , in chondrosarcomas (UrõÂ a et al., 1998), primary and metastatic melanomas (Airola et al., 1999; Nikkola et al., 2001) , and urothelial carcinomas (BostroÈ m et al., 2000) . In SCCs of the skin, oral cavity, pharynx, larynx, and vulva MMP-13 is expressed primarily by cancer cells at the invading edge of the tumor and its expression correlates with the invasion capacity of the tumors (Airola et al., 1997; Cazorla et al., 1998; Etoh et al., 2000; Johansson et al., 1997a Johansson et al., , 1999 .
Tumor suppressor gene p53 induces cell cycle arrest and apoptosis and it is mutated and inactivated in various types of malignant tumors, including SCCs (Hollstein et al., 1991; Levine et al., 1991) . Wild-type p53 is a transcription factor, which activates transcription of its target genes by binding to a speci®c consensus sequence in the promoter consisting of two copies of a 10-bp DNA motif 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3', separated by 0 ± 13 bp (el-Deiry et al., , 1993 Kastan et al., 1992; Miyashita and Reed, 1995; Okamoto and Beach, 1994) . In addition, p53 can repress the expression of a variety of cellular and viral genes lacking the p53 binding site in the promoter (Kley et al., 1992; Miyashita et al., 1994; Santhanam et al., 1991; Werner et al., 1996) . p53 also regulates the proteolytic capacity of cells. The promoter of gelatinase-A (MMP-2) contains a consensus p53 binding element, which mediates activation of MMP-2 gene transcription (Bian and Sun, 1997) . Furthermore, it has been shown that wild-type and mutant p53 dierentially regulate human MMP-1 and MMP-13 promoter activity in synovial cells (Sun et al., 1999 suggesting a role for p53 inactivation in the cartilage destruction in rheumatoid arthritis. In the present study, adenovirusmediated expression of wild-type p53 resulted in potent inhibition of MMP-13 and MMP-1 expression by SCC cells and inhibited their invasion independently of its proapoptotic eect, providing evidence for a novel antiinvasive role of p53.
Results

Adenoviral delivery of p53 suppresses expression of MMP-13 and MMP-1 in SCC cells
Mutation and inactivation of tumor suppressor gene p53 is a common event in distinct types of human cancers, including SCCs (Hollstein et al., 1991; Levine et al., 1991) . In addition to promoting cell cycle arrest and apoptosis, p53 has been shown to regulate the promoter activity of invasion associated proteinases, MMP-1, MMP-2, and MMP-13 (Bian and Sun, 1997; Sun et al., 1999 . To elucidate the possible eect of wild-type p53 on the invasive capacity of SCC cells, we ®rst infected a metastatic human cutaneous SCC cell line (UT-SCC-7) with one mutant p53 allele (Table  1) with recombinant adenovirus RAdp53, which harbors wild-type p53 gene, and determined MMP-13 and MMP-1 mRNA expression 24 and 48 h later by Northern blot hybridizations. Transduction of UT-SCC-7 cells with RAdp53 at MOI 700 resulted in potent reduction (81%) in MMP-13 mRNA levels 24 and 48 h after p53 gene delivery (Figure 1a) . Adenoviral delivery of wild-type p53 gene also resulted in suppression of MMP-1 mRNA expression (29 and 46%) 24 and 48 h after infection, respectively ( Figure  1a) . Infection of UT-SCC-7 cells with empty control adenovirus RAd66 slightly reduced MMP-13 mRNA levels, but not MMP-1 or GAPDH mRNA abundance, as compared to uninfected cells (Figure 1a) .
Adenovirus-mediated expression of p53 also resulted in potent inhibition in MMP-13 production (by 85 to 88%) noted at 24 and 48 h after adenoviral infection of UT-SCC-7 cells (Figure 1b ). In the same cells, production of MMP-1 was suppressed by 51% at 24 h and by 44% at 48 h after infection with RAdp53. In contrast, p53 had no eect on TIMP-1 production by these cells (Figure 1b) . Infection of cells with empty adenovirus RAd66 slightly reduced MMP-13 production, but not MMP-1 or TIMP-1 production ( Figure  1b) . The eect of adenoviral p53 gene delivery on the expression of MMP-13 and MMP-1 was tested in altogether four head and neck SCC cell lines with dierent p53 mutations. In all cell lines marked inhibition (71 ± 92%) of MMP-13 production in response to exogenous p53 was noted (Table 1 ). In addition, production of proMMP-1 was inhibited by 26 ± 93% by p53 (Table 1) .
Invasive tumor cells of SCCs of the head and neck and vulva express 92 kDa and 72 kDa gelatinases (MMP-9 and -2) (Johansson et al., 1999; Pyke et al., 1992) . In addition, wild-type p53 has been shown to stimulate the activity of MMP-2 gene promoter (Bian and Sun, 1997) . In this context, we also examined the eect of adenovirally delivered wild-type p53 on the gelatinolytic activity of SCC cells. As shown in Figure  1c , infection with RAdp53 had no marked eect on basal production of MMP-9 or MMP-2 by UT-SCC-7 cells. Similarly, the expression of 92 kDa and 72 kDa 
The effect of p53 expression on viability of SCC cells
In addition to cell cycle arrest, prolonged p53 expression also results in induction of programmed cell death (see Hupp et al., 2000) . To exclude the possibility that the reduction in MMP-13 and MMP-1 production by p53 would be due to reduced cell viability we determined the viability of SCC cells following adenoviral delivery of wild-type p53. No signi®cant reduction in the number of viable cells was detected within the ®rst 24 h after infection with RAdp53 as compared to the RAd66 infected or uninfected control cells, indicating that its inhibitory eect on MMP-13 and MMP-1 expression 24 h after RAdp53 infection is not due to reduced cell viability ( Figure 2a ). However, 48 h after RAdp53 infection the number of viable UT-SCC-7 cells was reduced by 50%, and 8 days after RAdp53 infection nearly all cells were dead ( Figure 2a ). No reduction in cell viability was noted in RAd66 infected cells at any time point.
To further exclude the possibility, that inhibition of MMP-13 and MMP-1 expression by wild-type p53 is due to onset of apoptosis we stained RAdp53 infected cells with the DNA dye (Hoechst 33342) 24 and 48 h after the infection. No alterations in nuclear morphology as sign of apoptosis were detected in UT-SCC-7 cells 24 h after adenoviral delivery of wild-type p53 gene ( Figure 2b , middle panel). However, immunostaining of same cultures with MMP-13 monoclonal antibody con®rmed that transduction of cells with RAdp53 resulted in marked reduction in MMP-13 expression, as compared to uninfected and RAd66 infected cultures, in which prominent cytoplasmic staining was noted ( Figure 2b , left panel). However, apoptotic bodies, i.e. nuclear condensation were seen in the UT-SCC-7 cells infected with RAdp53 after 48 h, whereas in uninfected and RAd66 infected cells nuclei remained intact (Figure 2b , right panel). These results show, that suppression of MMP-13 expression in response to wild-type p53 within 24 h is not dependent on onset of apoptosis, which takes place during the next 24 h.
p53 up-regulates p21
Waf1/Cip1 in SCC cells
Wild-type p53 inhibits cell growth by activating a set of genes involved in cell cycle regulation. The expression of cyclin-dependent kinase (CDK) inhibitor p21
is induced by p53 resulting in subsequent G1 arrest (Kastan et al., 1995) . To con®rm the function of A marked induction in p21 Waf1/Cip1 was noted by Western blot analysis 24 h after p53 delivery into SCC cells (Figure 3a) . In contrast, the levels of another CDK inhibitor, p27
Kip1 were not altered ( Figure 3a ) indicating speci®city of the eect of adenovirally delivered p53 on SCC cells. Marked basal expression of p53 was detected in the same uninfected cells and after infection with RAd66 and increased levels were noted in cells infected with RAdp53 (Figure 3a) .
Immunostaining of UT-SCC-7 cells with a p21
Waf1/Cip1 antibody con®rmed induction and nuclear localization of p21
Waf1/Cip1 24 h after adenoviral p53 delivery (Figure 3b ). In contrast, cells infected with empty control virus, RAd66 or uninfected cells showed no marked p21
Waf1/Cip1 staining. In accordance with the observations above, Hoechst staining of the same cells revealed no signs of apoptosis 24 h after RAdp53 infection (Figure 3b ). Induction of p21
Waf1/Cip1 expression in response to wild-type p53 expression was also noted in two other SCC cell lines (Table 1) . However, one cell line (UT-SCC-15), which expressed low basal levels of p53 did not express detectable levels of p21 Waf1/Cip1 without stimulation or in response to adenoviral p53 expression (Figure 3c ). Nevertheless, infection of UT-SCC-15 cells with RAdp53 resulted in marked inhibition in MMP-13 expression (Figure 3d , Table 1 ). Expression of MMP-1 by UT-SCC-15 cells was also inhibited 24 h after exogenous p53 delivery but to a lesser degree. Expression level of p27
Kip1 was not altered in UT-SCC-15 cells infected with RAdp53 (Figure 3c ). These results provide evidence, that suppression of MMP-13 expression by p53 does not require presence of functional p21
Waf1/Cip1 . The levels of p53 in uninfected control cells and RAd66 infected UT-SCC-15 cells were low, but marked expression was detected in RAdp53 infected cells (Figure 3c ).
p53 inhibits enhancement of MMP-13 expression by TGF-b and TNF-a
Given the potent inhibition of MMP-13 expression by wild-type p53, we also examined its eect on MMP-13 production in combination with tumor necrosis factor-a (TNF-a) and transforming growth factor-b1 (TGF-b1) known to stimulate the expression of MMP-13 in SCC cells (Johansson et al., 1997b (Johansson et al., , 1999 Ala-aho et al., 2000) . As shown in Figure 4 , the production of MMP-13 was potently (20-fold) enhanced by TNF-a and to a lesser extent (3.7-fold) by TGF-b1 both in uninfected and RAd66 infected cells. Again, infection of UT-SCC-7 cells with RAdp53 alone markedly reduced MMP-13 abundance (Figure 4) . Interestingly, infection of cells with RAdp53 potently suppressed the stimulation of MMP-13 mRNA expression by TNF-a (by 47%) and TGF-b (by 34%). In comparison, up-regulation of MMP-1 by TGF-b and TNF-a was less potent (3.4-and 4.1-fold) in uninfected cells and was also suppressed by wild-type p53 expression by 34 and 47%, respectively (Figure 4 ).
p53 inhibits invasion of SCC cells
As compared to other collagenolytic MMPs, MMP-13 potently degrades components of basement membranes . Accordingly, we have noted, that the expression of MMP-13 enhances invasion of malignant cells through reconstituted basement membrane, Matrigel (Ala-aho et al., 2002). As p53 potently inhibits the expression of MMP-13, we examined its eect on the invasion of SCC cells through Matrigel. To avoid the eect of p53 on the viability of SCC cells we were forced to limit the invasion assays within the ®rst 24 h after adenoviral infection. As shown in Figure 5 , invasion of UT-SCC-7 cells was signi®cantly inhibited (by 35%) by expression of wild-type p53, whereas infection of UT-SCC-7 cells with empty control virus RAd66 had no eect on the invasion capacity of UT-SCC-7 cells. These results provide evidence, that wild-type p53 inhibits the invasion capacity of SCC cells, most likely due to suppression in the expression of MMP-13. 
Discussion
In the present study, we show that adenovirusmediated delivery of wild-type p53 into cell lines derived from head and neck SCCs with mutated p53 resulted in signi®cant reduction in collagenase-3 (MMP-13) expression, as determined by Northern blot and Western blot analysis and by immunocytochemistry. Previous observations by us and others show, that MMP-13 is speci®cally expressed by tumor cells at the invading edge of SCCs of the head and neck and vulva (Airola et al., 1997; Cazorla et al., 1998; Johansson et al., 1997a Johansson et al., , 1999 , and that inhibition of MMP-13 expression in invasive transformed human epidermal keratinocytes markedly reduces their invasion capacity (Ala-aho et al., 2000; Johansson et al., 2000b) . Expression of cyclin dependent kinase inhibitor p21 Waf1/Cip1 was induced as a marker of the function of exogenously delivered p53 in these cells. The speci®city of the cellular response to adenovirally delivered p53 was shown by the fact, that the expression of p27 Kip1 , another cdk inhibitor that induces arrest in G1 phase of cell cycle, was not altered in p53 overexpressing cells. An interesting ®nding was that the expression of MMP-13 was inhibited by 71% in response to adenoviral p53 expression also in cell line UT-SCC-15, . This indicates that inhibitory mechanism of p53 on MMP-13 expression does not require activation of p21 Waf1/Cip1 expression in these cells. In general, p53 mediates apoptosis through a linear pathway involving Bax transactivation, Bax translocation from the cytosol to membranes, cytochrome c release from mitochondria, and caspase-9 activation, followed by the activation of caspase-3, -6, and -7 (Shen and White, 2001 ). Our results show marked reduction in MMP-13 and MMP-1 expression already within the ®rst 24 h after adenoviral delivery of wildtype p53 gene, whereas no alterations in nuclear morphology could be detected at this point. In addition, cell viability was not altered 24 h after p53 gene delivery, as determined by MTT assay, which is a sensitive method for detecting alterations in mitochondrial function, an early sign of onset of apoptotic machinery by p53. These results provide evidence, that the apoptotic signaling cascade of p53 has not been activated at this time point, and that p53 inhibits MMP-13 and MMP-1 gene expression independently of its ability to induce apoptosis. In addition, adenoviral p53 gene delivery had no marked eect on GAPDH mRNA levels, or on production of MMP-2, MMP-9, or TIMP-1, indicating that the inhibitory eect of p53 on MMP-13 and MMP-1 expression is not due to general reduction in mRNA stability. Our results also show, that MMP-13 and MMP-1 mRNA levels or production are not further reduced between 24 and 48 h after adenoviral p53 gene delivery, although a 50% reduction in cell viability and the presence of apoptotic cells was noted at 48 h time-point. These observations indicate, that altered cell viability and apoptosis have no inhibitory eect on MMP-13 and MMP-1 expression. Adenoviral expression of p53 also suppressed the invasion capacity of SCC cells through Matrigel within the ®rst 24 h after transduction. Based on these results, it can be proposed, that p53 exerts a biphasic eect as a tumor suppressor: it has an early inhibitory eect on the expression of ECM degrading invasion proteinases (MMP-13, MMP-1), followed by onset of apoptosis.
Human collagenase-3 (MMP-13) is not expressed by normal epidermal keratinocytes in culture or in vivo (Johansson et al., 1997b; Vaalamo et al., 1997) , but it is expressed by malignantly transformed epidermal keratinocytes, i.e. squamous carcinoma cells in culture and in vivo (Johansson et al., 1997a (Johansson et al., , 1999 . However, no expression of MMP-13 was noted in premalignant tumors in human skin. These observations show, that MMP-13 expression serves as a marker for transformation of squamous epithelial cells and suggest a role for MMP-13 in invasion of SCC cells. Expression of MMP-13 was also noted in spontaneously transformed human epidermal keratinocyte cell line, HaCaT, which harbors mutated p53 in both allels. Previous observations also show, that mutant forms of p53 lack the ability to suppress the activity of human MMP-13 promoter and some mutants can stimulate the promoter activity . Our previous observations on vulvar SCCs show, that inactivation of p53 alone is neither essential nor sucient for induction of MMP-13 expression in squamous epithelial cells (Johansson et al., 1999) . However, all SCC cell lines examined here harbored inactivating mutations of p53 and displayed marked basal expression of MMP-13. The results presented here together with the previous observations discussed above, provide evidence, that p53 plays an important role in suppression of MMP-13 expression in transformed keratinocytes.
Previous studies have shown, that p53 can control the proteolytic capacity of cells by regulating the expression of distinct MMPs. It was shown, that wildtype p53 binds to its cognate cis-element in the promoter of human MMP-2 gene and stimulates the Figure 4 Wild-type p53 inhibits enhancement of MMP-13 and MMP-1 expression by TGF-b and TNF-a. UT-SCC-7 cells were infected with RAd66 and RAdp53 at MOI 700 for 6 h prior to adding TGF-b1 (5 ng/ml) or TNF-a (20 ng/ml). After 24 h incubation samples of conditioned medium were analysed for MMP-13 and MMP-1 production by Western blotting Figure 5 Invasion of UT-SCC-7 cells is inhibited by p53. Cell culture inserts were pre-coated with 25 mg Matrigel. UT-SCC-7 cells were infected with RAd66 or RAdp53 at MOI 700 for 6 h and seeded on top of Matrigel. The number of invaded cells were determined after 24 h. Mean+s.e.m. of three experiments performed in duplicate are shown. Statistical signi®cance determined by Student's t-test, as compared against uninfected control cells: *P=0.0065 p53 inhibits MMP-13 expression R Ala-aho et al promoter activity in transiently transfected osteosarcoma cells (Bian and Sun, 1997) . In contrast, wild-type p53 suppresses the activity of human MMP-1 gene promoter (Sun et al., 1999) . In addition, promoter of human MMP-13 gene contains a putative p53 binding element at position 7123 to 797 with respect to transcription start site, and mutated forms of p53 have been shown to stimulate the activity of human MMP-13 promoter in transiently transfected synovial cells . However, the role of wild-type p53 in the regulation of the expression of these endogenous MMP genes has not been known. Our results show for the ®rst time, that in human SCC cells wild-type p53 potently suppresses the expression of MMP-13 and MMP-1, but has no eect on the production or activation of MMP-2 and MMP-9. It is possible, that the eects of wild-type p53 are cell-type speci®c, as the stimulation of MMP-2 promoter was detected in human osteosarcoma and ®brosarcoma cells. Further evidence for the role of p53 as an anti-invasive gene product has been provided by observations that wildtype p53 suppresses expression of tissue type and urokinase type plasminogen activators (Kunz et al., 1995) and activates expression of serine protease inhibitors plasminogen activator inhibitor-1 and maspin in malignant cells (Kunz et al., 1995; Zou et al., 2000) . The therapeutic ecacy of adenoviral delivery of wildtype p53 has been examined in phase I and II clinical trials in patients with recurrent or metastatic SCCs of the head and neck (Liu et al., 1994 (Liu et al., , 1995 Clayman et al., 1998; . These trials, as well as preclinical studies with p53 adenovirus have demonstrated the ability of wild-type p53 to promote apoptosis of cancer cells and suppress tumor progression in vivo. The results presented here provide evidence for an additional mechanism for p53-elicited suppression of tumor growth in vivo, i.e. inhibition of tumor invasion. In general, one of the limiting factors in wild-type p53 based gene therapy is clearly the restricted transduction eciency that can be obtained by current replication-de®cient adenoviral vectors in vivo. Nevertheless, the results of the present study provide evidence, that p53 possesses features of an ideal tumor suppressor gene for gene therapy of cancer and may be feasible in combination with other forms of cytoreductive therapy. In conclusion, our results show, that p53 is a potent tumor suppressor, which possesses two temporally distinct anti-tumor eects on malignantly transformed squamous epithelial cells: it displays an anti-invasive eect early after p53 gene delivery followed by induction of programmed cell death.
Materials and methods
SCC cell cultures
Human SCC cell lines were established from primary tumors or metastasis (UT-SCC-7) of SCCs of the head and neck (Table 1) (Lansdorf et al., 1999) , and cultured in DMEM supplemented with 6 mmol/l glutamine, nonessential amino acids, and 10% fetal calf serum (FCS). p53 status of the UT-SCC cell lines (Table 1) has been determined previously (Servomaa et al., 1996; Eicheler et al., 2002) .
Adenoviral cell infections
To determine the adenoviral infection eciency, SCC cells were transduced with recombinant adenovirus RAdlacZ, which harbors the Escherichia coli b-galactosidase gene (lacZ) under the control of CMV IE promotor (Wilkinson and Akrigg, 1992) (kindly provided by Dr Gavin WG Wilkinson, University of Cardi, Wales). Cells (5610 5 ) were plated, the next day RAdlacZ was added to cultures at dierent multiplicity of infection (MOI), cultures were incubated for 6 h, washed with PBS, and maintained for 16 h in DMEM containing 0.5% FCS. The cells were ®xed and stained for bgalactosidase activity, as described previously (Ravanti et al., 1999) . In experiments, cells were infected with wild-type p53 adenovirus RAdp53 (Katayose et al., 1995) or with empty virus RAd66 (Wilkinson and Akrigg, 1992) at appropriate MOI (400 to 2000) and incubated for 6 h in DMEM with 0.5% FCS. Medium was changed and incubations were continued for indicated periods of time.
RNA analysis
Total RNA was isolated from cells using modi®ed single-step phenol/chloroform extraction (Chomczynski and Sacchi, 1987) . Aliquots of total RNA (15 mg) were analysed by Northern blot hybridizations as described previously (Alaaho et al., 2000) , using cDNA probes labeled with [a-32 P]dCTP by random priming. For hybridizations, a 1.6 kb human MMP-13 cDNA (Johansson et al., 1997b) , a 2.0 kb human MMP-1 cDNA (Goldberg et al., 1986 ) and a 1.3 kb rat GAPDH cDNA (Fort et al., 1985) were used as probes. The 32 P-labeled cDNA-mRNA hybrids were visualized by autoradiography, quantitated by scanning densitometry and corrected for the levels of GAPDH transcripts in the same RNA samples.
Assay of MMP-13, MMP-1, and TIMP-1 production The production of MMP-13 and MMP-1 by SCC cells was determined by Western blot analysis, as described previously (Ala-aho et al., 2000) . Equal aliquots of the conditioned media of cells were fractionated on 10% SDS ± PAGE, transferred to Hybond ECL ®lter (Amersham), and the amounts of MMP-13 and MMP-1 were determined using monoclonal antibody (181-15A12) against human MMP-13 (Calbiochem, San Diego, CA, USA) in dilution 1 : 100 and rabbit polyconal antibody against human MMP-1 (kindly provided by Dr H Birkedal-Hansen, NIDR, Bethesda, MD, USA) in dilution 1 : 5000, followed by detection of speci®cally bound primary antibodies with peroxidase-conjugated secondary antibodies and visualized by enhanced chemiluminescence (ECL; Amersham). For TIMP-1 analysis, aliquots of conditioned media were reduced with 5% b-mercaptoethanol prior to electrophoretic fractionation and were analysed with polyclonal rabbit antibodies (Chemicon International Inc., Temecula, CA, USA) in dilution 1 : 1000.
Gelatin zymography
Aliquots of conditioned media were fractionated on 10% SDS ± PAGE containing 1 mg/ml gelatin (G-9382; Sigma) and 0.5 mg/ml 2-methoxy-2,4-diphenyl-3(2H)-furanone (FluOncogene p53 inhibits MMP-13 expression R Ala-aho et al ka 645989) (O'Grady et al., 1984) . The gels were washed for 30 min in 50 mM Tris, 0.02% NaN 3 and 2.5% Triton X-100, pH 7.5 and for 30 min in the same buer supplemented with 5 mM CaCl 2 and 1 mM ZnCl 2 (Heussen and Dowdle, 1980) . The gels were then incubated in 50 mM Tris, 0.02% NaN 3 , 5 mM CaCl 2 and 1 mM ZnCl 2 for 24 h at 378C, ®xed in 50% methanol/7% acetic acid, stained with 0.2% Coomassie Blue G250 and photographed as previously described (Ala-aho et al., 2000) .
Assay of p53, p27
Kip1 , and p21 Waf1/Cip1 levels Cell lysates derived from RAdp53, RAd66 or uninfected SCC cells were fractionated by 10% SDS ± PAGE and transferred to Hybond ECL ®lter (Amersham). Filters were blocked with 5% non-fat dry milk in TBS-Tween and the amounts of p53, p27 Kip1 and p21 Waf1/Cip1 were determined by Western blot analysis using monoclonal antibody speci®c for human p53 (DO-1; Santa Cruz Biotechnology; Santa Cruz, CA, USA; 200 ng/ml), monoclonal antibody against human p27 Kip1 (K25020; Transduction Laboratories, Lexington, KY, USA; 250 ng/ml) and monoclonal antibody against human p21
Waf1/Cip1 (15441A; Pharmingen, San Diego, CA, USA; 200 ng/ml). The membranes were washed three times, incubated with peroxidase-conjugated secondary antibodies and speci®c binding visualized by ECL.
Immunostaining of SCC cells
Adenovirus infected SCC cells were cultured in the presence of 0.5% FCS in DMEM on glass slides for 24 h, washed with PBS, ®xed with ice-cold methanol and washed with PBS. After blocking with 3% BSA in PBS, the cells were incubated for one hour at room temperature with mouse monoclonal antibodies against human MMP-13 (1.25 mg/ml) and p21 Waf1/Cip1 (2.5 mg/ml). After rinsing the primary antibodies, cells were incubated with FITC-labeled anti-mouse antibody (Calbiochem 401234) 1 h at room temperature, washed and nuclei were counterstained with Hoechst-33342 (10 mg/ml).
Determination of cell viability
For determination of cell viability, 1610 4 cells were seeded on 96 well plates and incubated for dierent periods of time after the adenovirus infection. The number of viable cells was determined by CellTiter 96 TM AQueous non-radioactive cell proliferation assay (Promega, Madison, WI, USA) according to manufacturer's instructions.
Invasion assays
The invasion assays were performed as previously described (Ala-aho et al., 2000) . Cell culture inserts (Falcon 3097, Becton Dickinson) with 8.0 mm pore size were coated with 25 mg of reconstituted basement membrane (Matrigel, Becton Dickinson). For invasion assays, cells were infected with adenoviruses as descibed above. Six hours later, cells (10 5 / chamber) suspended in DMEM containing 0.1% BSA were placed on top of the gel in the upper chamber in a ®nal volume of 200 ml, with DMEM (700 ml) containing 10% FCS as chemoattractant in the lower chamber. After 24 h, cells on the upper surface were gently removed with a cotton bud and the invaded cells on the lower surface were ®xed in 2% paraformaldehyde, counterstained with 0.1% crystal violet, and counted.
